Two months after closing a $100 million Series A — oversubscribed, co-led by RA Capital, a16z Bio+Health, and Nextech Invest — Stipple Bio has moved fast enough to lock in a manufacturing and technology partner before its lead program ever touches a patient. That sequencing matters. In ADC development, platform access and conjugation chemistry are strategic bottlenecks, not afterthoughts, and securing them at the preclinical stage signals a company building toward clinical execution rather than discovery theater.
The deal gives Stipple Bio target-specific access to Lonza’s GlycoConnect® site-specific conjugation technology, HydraSpace® polar spacer, and toxSYN® linker-payload — a stack Lonza describes as clinically validated through its use across multiple partner ADC programs. The commercial structure is conventional: Lonza receives milestone payments across clinical, regulatory, and commercial gates, plus royalties, while retaining manufacturing responsibility for its proprietary components. Stipple Bio owns the research, development, and commercialization obligations. What’s unconventional is the multi-target scope, which preserves Stipple Bio’s ability to run the same conjugation chemistry across its broader pipeline rather than renegotiating deal terms program by program. That flexibility is a real structural advantage for a company whose entire thesis — the Pointillist Platform — rests on identifying multiple tumor-specific epitopes, not a single target.
That thesis deserves scrutiny. The ADC field is crowded and the biology is unforgiving. On-target/off-tumor toxicity has killed programs with strong preclinical rationales, and the difference between a usable therapeutic index and a failed Phase I often comes down to epitope selection as much as linker chemistry. Stipple Bio’s claim is that epitope-level precision — identifying cell surface conformations expressed on tumor cells but not normal tissue — solves the targeting problem upstream, before conjugation chemistry matters. STP-100, with its target and indication still undisclosed, is expected to enter early clinical studies in early 2027. The $100 million runway and this Lonza agreement together suggest the company is tracking toward that timeline with deliberate infrastructure.
The single number worth watching is when STP-100’s IND goes active. An early 2027 filing would validate the platform’s preclinical-to-clinical translation speed; a slip would raise questions about whether epitope identification at the precision Stipple Bio claims is reproducible enough to industrialize across a multi-target pipeline.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
